111 related articles for article (PubMed ID: 38741354)
1. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
3. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
4. V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia.
Arora N; Nair S; Pai R; Nair S; Ahmed R; Abraham A; Viswabandya A; George B; Balasubramanian P; Srivastava A; Mathews V
Indian J Pathol Microbiol; 2015; 58(1):62-5. PubMed ID: 25673595
[TBL] [Abstract][Full Text] [Related]
5. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Kreitman RJ; Wilson W; Calvo KR; Arons E; Roth L; Sapolsky J; Zhou H; Raffeld M; Stetler-Stevenson M
Clin Cancer Res; 2013 Dec; 19(24):6873-81. PubMed ID: 24277451
[TBL] [Abstract][Full Text] [Related]
6. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
7. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Arons E; Suntum T; Stetler-Stevenson M; Kreitman RJ
Blood; 2009 Nov; 114(21):4687-95. PubMed ID: 19745070
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.
Salem DA; Scott D; McCoy CS; Liewehr DJ; Venzon DJ; Arons E; Kreitman RJ; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2019 Jul; 96(4):275-282. PubMed ID: 31077558
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
11. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
Broccoli A; Argnani L; Nanni L; Terragna C; Sabattini E; Gabrielli G; Stefoni V; Pellegrini C; Casadei B; Morigi A; Lolli G; Carella M; Coppola PE; Zinzani PL
Am J Hematol; 2021 Oct; 96(10):1204-1210. PubMed ID: 34245477
[TBL] [Abstract][Full Text] [Related]
12. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG; Byrd JC; Abramson JS; Bhat S; Bociek G; Brander D; Brown J; Chanan-Khan A; Coutre SE; Davis RS; Fletcher CD; Hill B; Kahl BS; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Lancet J; Ma S; Malek S; Mosse C; Shadman M; Siddiqi T; Stephens D; Wagner N; Zelenetz AD; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2017 Nov; 15(11):1414-1427. PubMed ID: 29118233
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
14. [Hairy cell leukemia and pregnancy].
Al-Radi LS; Moiseeva TN; Smirnova SY; Shmakov RG
Ter Arkh; 2017; 89(7):99-104. PubMed ID: 28766548
[TBL] [Abstract][Full Text] [Related]
15. Molecular variant of hairy cell leukemia with poor prognosis.
Arons E; Kreitman RJ
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):99-102. PubMed ID: 21599610
[TBL] [Abstract][Full Text] [Related]
16. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Goodman GR; Burian C; Koziol JA; Saven A
J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
[TBL] [Abstract][Full Text] [Related]
17. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
18. [Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine].
Wang TY; Li ZJ; Lyu R; Fu MW; Sui WW; Huang WY; Liu W; An G; Deng SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):491-495. PubMed ID: 30032567
[No Abstract] [Full Text] [Related]
19. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
Yousaf M; Khan MA; Iftikhar R; Chaudary QU; Shahbaz N; Ahmad U; Javed H
J Ayub Med Coll Abbottabad; 2022; 34(4):797-801. PubMed ID: 36566402
[TBL] [Abstract][Full Text] [Related]
20. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]